AIA-PACK TPOAB ASSAY
K981521 · Tosoh Medics, Inc. · JZO · Oct 8, 1998 · Immunology
Device Facts
| Record ID | K981521 |
| Device Name | AIA-PACK TPOAB ASSAY |
| Applicant | Tosoh Medics, Inc. |
| Product Code | JZO · Immunology |
| Decision Date | Oct 8, 1998 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 866.5870 |
| Device Class | Class 2 |
Intended Use
AIA-PACK TPOAb is intended for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of anti-thyroid peroxidase antibodies (TPOAb) in human serum on specific TOSOH AIA System analyzers. Measurements obtained by this device aid in the diagnosis of autoimmune thyroid disorders, such as Graves' disease and Hashimoto's disease.
Device Story
AIA-PACK TPOAb assay is an in vitro diagnostic reagent kit used on TOSOH AIA System analyzers. It measures anti-thyroid peroxidase antibodies in human serum samples. The device is operated by laboratory personnel in clinical settings. The system performs quantitative analysis to assist clinicians in diagnosing autoimmune thyroid conditions like Graves' disease and Hashimoto's disease. Results are provided to healthcare providers to support clinical decision-making regarding thyroid health.
Clinical Evidence
No clinical data provided in the document; substantial equivalence determination based on 510(k) regulatory review process.
Technological Characteristics
In vitro diagnostic reagent kit for quantitative immunoassay; designed for use on TOSOH AIA System analyzers; utilizes serum samples; methodology involves antibody detection for thyroid disorder diagnosis.
Indications for Use
Indicated for in vitro diagnostic quantitative measurement of anti-thyroid peroxidase antibodies (TPOAb) in human serum to aid in the diagnosis of autoimmune thyroid disorders, including Graves' disease and Hashimoto's disease.
Regulatory Classification
Identification
A thyroid autoantibody immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the thyroid autoantibodies (antibodies produced against the body's own tissues). Measurement of thyroid autoantibodies may aid in the diagnosis of certain thyroid disorders, such as Hashimoto's disease (chronic lymphocytic thyroiditis), nontoxic goiter (enlargement of thyroid gland), Grave's disease (enlargement of the thyroid gland with protrusion of the eyeballs), and cancer of the thyroid.
Related Devices
- K981522 — AIA-PACK TGAB ASSAY · Tosoh Medics, Inc. · Oct 8, 1998
- K991096 — IMMULITE 2000 ANTI-TPO AB, MODEL L2KT02, L2KT06 · Diagnostic Products Corp. · May 13, 1999
- K984163 — ANTI-TPO EIA DIAGNOSTIC TEST KIT · The Binding Site, Ltd. · Feb 2, 1999
- K020348 — ABBOTT AXSYM ANTI-THYROID-PEROXIDASE, MODELS5F57 COMPRISING STANDARDS/CALIBRATORS · Axis-Shield Diagnostics, Ltd. · May 2, 2002
- K033977 — ZEUS SCIENTIFIC, INC., ATHENA MULTI-LYTE TPO/TG IGG TEST SYSTEM · Zeus Scientific, Inc. · Mar 22, 2004
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/2 description: The image shows the seal of the U.S. Department of Health & Human Services. The seal features an abstract image of an eagle with three human profiles within its body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.
## OCT 8
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Lori Robinson Manager, Quality Assurance TOSOH Medics, Inc. 373 D Vintage Park Drive Foster City, California 94404
Re: K981521/S1
> Trade Name: AIA-PACK TPOAb Assay Requlatory Class: II Product Code: JZO Dated: June 26, 1998 Received: July 14, 1998
Dear Ms. Robinson:
We have reviewed your Section 510 (k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the requlation entitled, "Misbranding by reference to premarket notification"(21 CFR 807:97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Image /page/2/Picture/0 description: The image shows the logo for TOSOH MEDICS, INC. The logo consists of a stylized four-leaf clover shape with a square in the center, along with the text "TOSOH MEDICS, INC." The word "TOSOH" is also written in a smaller font below the clover shape. The logo is simple and professional, and it is likely used to represent the company's brand.
K98152
## PREMARKET NOTIFICATION
## INDICATION FOR USE STATEMENT
## AIA-PACK TPOAb Assay
AIA-PACK TPOAb is intended for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of anti-thyroid peroxidase antibodies (TPOAb) in human serum on specific TOSOH AIA System analyzers. Measurements obtained by this device aid in the diagnosis of autoimmune thyroid disorders, such as Graves' disease and Hashimoto's disease.
Peter E. Macfmi.
Division Sic 510(k) Number